The purpose of this study was to investigate the feasibility of interventional MRI-guided local agent delivery into pig common bile duct (CBD) walls using a newly designed MR-compatible, needle-integrated balloon catheter system.
INTRODUCTION
Pancreatobiliary cancer remains one of the deadliest malignant diseases worldwide. Approximately 9000 new cases of biliary cancer and 46 000 cases of pancreatic cancer are diagnosed in the United States each year (1, 2) . Due to the lack of early symptoms and the tendency of the tumor to invade surrounding structures or metastasize at an early stage, most patients have advanced disease at the time of their diagnosis. The fiveyear survival rate is less than 5%. Although surgical resection offers the only potential chance of cure for patients with pancreatobiliary cancers (1) (2) (3) , unfortunately very few patients have the chance to receive the surgical treatment due to the advanced stage of the disease with pervasive metastasis at presentation (3) (4) (5) . In current clinical practice, the only direct treatment for pancreatobiliary tumors involves systemic chemotherapy with or without radiation therapy. However, the benefits of systemic chemotherapy are limited by its non-specific delivery, which results in low drug doses at the targeted malignant biliary regions and systemic toxicities to other organs (5-7).
MRI-guided minimally invasive interventional technology permits local delivery of high-dose drug to target tissues, which thus overcome the key drawback of systemic chemotherapeutic drug administration -toxicity to other vital organs. Recent efforts have been made to develop an intrabiliary local agent delivery approach, which may enable one to instantly monitor and evaluate the chemotherapeutic drug delivery efficacy of intrabiliary local agent delivery under MRI (8, 9) . This new technique involved the use of a multiporous balloon catheter that was percutaneously placed into the common bile duct (CBD), where chemotherapeutic drugs were locally infused into CBD walls. However, the infusion capability of the multiporous balloon has limited penetration depth of agents into the bile duct wall, and thereby deposits only a limited amount of chemotherapeutic drugs at the target bile duct (8) . This characteristic of the multiporous balloon is certainly not suitable for intrabiliary treatment of pancreatic head cancer, which, unlike biliary cancer growing along the bile duct wall, compresses and obstructs the distal CBD by a mass growing outside of the biliary tract. To solve this problem, we attempted to develop a technique of interventional MRI-guided local delivery of a sufficient dose of agents into deep-seated targets using an intrabiliary needle-integrated balloon catheter system.
MATERIALS AND METHODS

Design of the MR-compatible intrabiliary needle-integrated balloon catheter system
The needle-integrated balloon catheter system was comprised of a 22 G MR-compatible Chiba biopsy needle (MReye Disposable Chiba Biopsy Needle, Cook, Bloomington, IN, USA), which is used for MRI-guided biopsy in clinical practice, and a conventional 12 mm × 2 cm balloon catheter (Charger, Boston Scientific, Natick, MA, USA). The 3 mm long, 150°-curved tip of a 22G MR-compatible biopsy needle was restrained on the surface of the balloon and oriented perpendicular to the long axis of the catheter. The deflated balloon provided a protective covering for the curved needle tip, which ensured a smooth pass through the bile duct via a percutaneous access. Once the needleballoon system was positioned in the target bile duct segment, the puncture direction of the curved needle tip could be adjusted towards the target (such as a pancreatic head tumor mass). Subsequent full inflation of the balloon with saline can push the needle tip through the bile duct wall into the deepseated target, into which high-dose agent could be injected (Fig. 1) . The system can be fit into a 10 or 11 French sheath, which is placed in the CBD through a transcholecystic approach. With application of a vacuum, the balloon deflates, and the needle is retracted for removal of the device from the bile duct lumen.
Animal experiments
Animals
Pig experiments were approved by the Institutional Animal Care and Use Committee. Eight domestic pigs, 50-60 kg in weight, were sedated by intramuscular injection of Telazol at 4.4 mg/kg body weight and xylazine at 1 mg/kg body weight, and then mechanically ventilated with 1-3% isoflurane in 100% oxygen.
Catheterization of CBDs
A subcostal incision was made to expose the gallbladder. The gallbladder was mobilized and raised out of the peritoneal cavity. Under fluoroscopic guidance, an 11 French sheath (SafeSheath® Ultra, Pressure Products, San Pedro, CA, USA) was advanced, through the gallbladder and the cystic duct, into the CBD over a 0.035 inch hydrophilic guidewire (Terumo, Tokyo, Japan). Over the guidewire, we placed the intrabiliary needleballoon system in the distal portion of the CBD (Fig. 2(A) ). Then, we closed the abdominal incision in layers using interrupted non-absorbable sutures on the peritoneum, muscles and skin. The introducer was secured to the skin.
Intrabiliary chemotherapeutic drug delivery
Each animal was placed supine on the 3.0 T MR scanner table (Philips Healthcare, Best, The Netherlands). We acquired axial, sagittal and coronal fat-suppressed and respiration-gated T 1 -weighted images of bile duct walls and the needle-balloon system, using a Torso phase-array surface coil. Based on these MR images, we adjusted the position of the needle-balloon system to the target bile duct, and then inflated the needleintegrated balloon with 1% MultiHance (Bracco Diagnostics, Princeton, NJ, USA). Pre-injection MRI was performed with a turbo field echo sequence using 10/1 ms T R /T E , 300 mm field of view, 15°flip angle, 3 mm slice thickness, 320 × 320 matrix, and 4 Number of Excitations (NEX). Subsequently, through the needle channel, a 0.5 mL mixture solution, containing 5 mg 5-fluorouracil (5-FU), 125 μg motexafin gadolinium (MGd) and trypan blue dye, was injected into the CBD wall. Here trypan blue dye was used for subsequent histology analysis to confirm the penetration and distribution of agent in the bile duct wall and surrounding tissue. Thus, as a T 1 -weighted MR contrast agent and red fluorescence emitter, MGd was used for both instant MRI monitoring and subsequent histology confirmation by confocal microscopy. Immediately after agent administration, axial, sagittal and coronal fat-suppressed and respiration-gated T 1 -weighted MR images of bile duct walls were acquired, using the same parameters as described for pre-injection MRI. After MRI, the animals were transported back to the surgeryfluoroscopy lab, where a post-infusion cholangiogram was obtained to see any potential rupture of the injected CBDs by the new needle-balloon system.
Imaging analysis
We measured signal intensities (SIs) of the CBD walls and the peri-CBD tissues where the solution of 5-FU and MGd as well as trypan blue was injected. We calculated the average contrast-to-noise ratio (CNR) using the following equation: (SI CBD À SI peri-CBD )/SD noise, where SD noise is the standard deviation of the background noise. The 1 mm 2 region of interest was placed by an experienced radiologist. The penetration depth of MGd (starting from the inner bile duct wall) in the bile duct wall and surrounding tissue was measured as well.
Histology
Immediately after MRI, each animal was euthanized. The MGdtrypan blue-infused CBD segment or un-infused CBD segment (as a control) was harvested for histologic correlation to confirm the successful penetration of MGd-trypan blue into the CBD wall. We used optical imaging, at an excitation wavelength of 470 nm and emission wavelength of 750 nm, to display MGd emitting red fluorescence in the bile duct tissue. The small segments of bile ducts were cryosectioned at 8 μm and then examined using laser confocal microscopy to detect the red fluorescence of MGd.
Drug quantification
For 5-FU quantification in bile duct tissues, drug-delivered CBDs were harvested and homogenized in 5 mL PBS using a tissue grinder (Corning PYREX Ten Broeck, Corning, NY, USA). After centrifuging the suspension at 3000 rpm for 10 min, we extracted 5-FU by adding 2 mL of isopropyl alcohol and 5 mL of ethyl acetate to 0.5 mL samples; the suspension was vortexed and centrifuged for 10 min at 3000 rpm. The supernatant was then transferred to another tube and dried under a gentle stream of nitrogen. The dried samples were reconstituted in 200 μL mobile phase (water-methanol: 90-10) and analyzed using high-pressure liquid chromatography (HPLC) (Waters, Milford, MA, USA), using our established protocol. The linear regression analysis was performed by plotting the peak areas (y) of the drug against the respective concentration (x). Regression correlation coefficients of the lineal curve were above 0.990.
Statistical analysis
Statistical software (SPSS, version 19.0; SPSS, Chicago, IL, USA) was used for all data analysis. A paired t-test was used to compare the CNRs of the bile ducts with MRI between pre-and post-injection of the mixed solution into the CBD walls.
RESULTS
In all animals, intrabiliary injections of MGd and trypan blue dye were successfully performed. A post-infusion cholangiogram did not show any extravasation of X-ray contrast agent, which indicates no needle puncture-related injury of the injected bile duct walls (Fig. 2(B) ).
The needle-integrated balloon catheter used in this study could be clearly visualized on T 1 -weighted images as a dark structure in the CBD lumen, even though there was an artifact arising from the needle tip (Fig. 3(A), (B) ). These imaging features facilitated guidance of the needle/catheter in the bile duct, confirmation of the position of the needle tip, and adjustment of the puncture direction of the needle tip into the bile duct tissue. Following the needle puncture into the bile duct wall driven by the inflated balloon, MGd was successfully injected into the bile duct walls and surrounding tissues, demonstrated as a clear bright region extending from the needle tip into the bile duct wall and adjacent tissue (Fig. 3(C), (D) ). We achieved an average penetration depth of 4.7 ± 1.2 mm and an average MGd perfusion length of 21 ± 1.5 mm in the bile ducts and their surrounding tissues. The mixture of MGd and blue dye can perfuse with a broader scope in the loose peri-biliary tissue than the mechanical penetration depth of 3 mm needle tip. Intrabiliary post-injection of MGd caused a significant increase in regional SI compared with that of the pre-infusion on T 1 -weighted MR images. The average CNR of the post-infusion bile ducts was significantly higher than that of the pre-injection bile ducts (110.6 ± 22 versus 5.7 ± 2.8, p < 0.0001). We harvested the entire bile duct and surrounding tissue, including the hepatoduodenal ligament and portions of the duodenum and pancreas, for ex vivo optical imaging. Optical imaging showed the MGd infiltration in the bile duct wall and adjacent tissue, manifesting as bright red fluorescence in the MGd-injected region (Fig. 4(A) ), which was correlated with the blue dye staining in the same region (Fig. 4(B) ). Confocal microscopy further confirmed MGd penetration through the bile duct wall and surrounding tissue, featuring as red fluorescent dots in the cells and extracellular space, which was not seen in the control bile duct without the injection of MGd and trypan blue dye (Fig. 4(C), (D) ).
We plotted the peak areas (y) of the chemotherapeutic drug against its respective concentration (x). Regression correlation coefficients of the lineal curve were above 0.990. Quantitative analysis of 5-FU by HPLC showed that out of the total 5 mg of 5-FU injected into the bile duct tissue, 4.1 ± 0.12 mg 5-FU were retrieved, proving an approximately 80% drug delivery efficiency.
DISCUSSION
Pancreatic adenocarcinoma and cholangiocarcinoma are hypovascular and fibrosis-rich tumors, which make systemic chemotherapy less effective. The technique of intrabiliary MRIguided delivery of high-dose therapeutic agents into tumor masses had been developed in previous studies with an attempt to overcome the barrier that a limited amount of drug is delivered into the tumor cells, through a systemic administration route (8, 9) . The quantities of chemotherapeutic drugs delivered into the bile duct tissue through a multiporous balloon were less than 1 mg/g bile duct tissue, which means that the potential of translating this technique to clinical application is suboptimal (8) . To date, several balloon catheter-based intraluminal agent delivery techniques have been developed for locally administering therapeutics into vascular targets, such as passive diffusion by applying a double-occlusion balloon, pressure-driven infusion by a balloon with multiple micropores, and mechanically or electrically enhanced delivery (10) . The texture of pancreatobiliary cancers is very hard due to marked fibrosis and stromal myofibroblasts, which does not allow a high dose of therapeutic agents to enter the tumor tissues via the capabilities of passive diffusion or pressure-driven infusion approaches. We developed an MR-compatible needle-integrated balloon system. The advantage of this needle-balloon system is that it can be used to deliver drugs into tumors via a mechanical penetration mode with a sufficiently deep infiltration of delivered agents into the targets.
The results of our study have validated the feasibility of using the newly designed MR-compatible, needle-integrated balloon catheter system to locally deliver high dose agent into the deep-seated target of CBD, which can be accurately guided by clinical 3.0 T MRI. Interventional MRI is a valuable tool to monitor the penetration and distribution of MGd and 5-FU into CBD walls with significantly increased penetration depth and chemotherapeutic drug dosage in the biliary tissue. Thus, this technical development may specifically pose great value for locally treating pancreatic head adenocarcinoma by local administration of a high quantity of therapeutic agents into the tumor masses using this new needle-balloon catheter system. MRI has been used to guide interventions and cancer biopsies (11) (12) (13) (14) (15) . The advantages of MRI include 3D steering of the imaging plane, excellent soft tissue contrast, elimination of iodinated contrast agents, and no risk of ionizing radiation. During MRI-guided intervention, high-resolution anatomic and functional imaging can be performed to quantify the delivered agent within the target tissues (13, 14, 16, 17) . An interventional MRI technique can accurately guide the deployment of the needleballoon system in the bile duct lumen, and allow the instant visualization of the needle puncture in the target. Our study demonstrates the potential of using this technique to treat pancreatobiliary cancers, and then immediately assess the infiltration scope and penetration depth of therapeutic agents in the tumor target. MRI can help us not only to validate the drug delivery efficiency but also to evaluate the tumor status regarding tumor size and staging once this technique can be translated into clinical application. When the needle-balloon system is deployed in the tumor region, we can precisely adjust it according to the information acquired from MR images of the tumors, and thereby achieve effective drug delivery. We used MGd as the bio-imaging marker to evaluate the efficacy of this interventional MRI-guided agent delivery technique. MGd has multifunctional features: (i) a chemotherapeutic agent for treating cancer (18) ; (ii) an intracellular T 1 MRI contrast agent for specifically indicating the successful delivery of drugs into the target tumor (19); (iii) an emitter of red-colored fluorescence for confirming the drug delivery by subsequent histology examination; and (iv) a sensitizer to radiation therapy (20) . A recent study reported that the intracellular internalization of MGd by cancer cells was in a concentration-dependent manner, which encouraged us to develop the interventional molecular MRI technique to guide the treatment of panceatobiliary cancers.
This study has primarily focused on the design and development of the new MR-compatible, needle-integrated balloon system. It would be highly valuable to test this new device and technique on a large animal model such as a swine model with pancreatic cancer or bile duct cancer. However, unfortunately no large animal models with pancreatic cancers or bile duct cancers are available around the world. It is warranted to further perform comprehensive studies using survival animals to evaluate the safety and long-term impact of this new technique on treatment of pancreatobiliary malignancies.
In conclusion, it is feasible to use the new MR-compatible, needle-integrated balloon catheter system for intrabiliary local agent delivery into CBD walls under MRI guidance, which may open new avenues for efficient management of pancreatobiliary malignancies using MR-guided interventional oncology.
